|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US9725710B2
(en)
|
2014-01-08 |
2017-08-08 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
SG11201608389RA
(en)
|
2014-04-07 |
2016-11-29 |
Minerva Biotechnologies Corp |
Anti-nme antibody
|
|
CN104004095B
(zh)
*
|
2014-06-04 |
2016-11-23 |
博生吉医药科技(苏州)有限公司 |
一种cd7纳米抗体、其编码序列及应用
|
|
SI3240805T1
(sl)
|
2014-12-15 |
2025-04-30 |
The Regents Of The University Of California |
Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
|
KR20190080992A
(ko)
|
2015-05-21 |
2019-07-08 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
|
US11655452B2
(en)
*
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US11236174B2
(en)
|
2016-01-12 |
2022-02-01 |
Crescendo Biologics Limited |
Therapeutic molecules
|
|
HK1259075A1
(zh)
|
2016-02-17 |
2019-11-22 |
Seattle Genetics, Inc. |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
CN105647946B
(zh)
*
|
2016-03-18 |
2019-09-20 |
江苏普瑞康生物医药科技有限公司 |
一种基于FcγRⅢa的嵌合基因及其用途
|
|
TWI761831B
(zh)
|
2016-04-01 |
2022-04-21 |
美商凱特製藥公司 |
嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
|
|
US10603380B2
(en)
*
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
GB201607968D0
(en)
|
2016-05-06 |
2016-06-22 |
Crescendo Biolog Ltd |
Chimeric antigen receptor
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
KR20190053835A
(ko)
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
JP7114490B2
(ja)
*
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
KR20190063458A
(ko)
*
|
2016-07-15 |
2019-06-07 |
포세이다 테라퓨틱스, 인크. |
Ｍｕｃ1에 특이적인 키메라 항원 수용체(ｃａｒｓ) 및 그의 사용 방법
|
|
PL240585B1
(pl)
*
|
2016-07-18 |
2022-05-02 |
Helix Biopharma Corp |
Chimeryczny receptor antygenowy (CAR), komórki immunologiczne zawierające CAR oraz kompozycja farmaceutyczna je zawierająca do leczenia nowotworów
|
|
CN114395048B
(zh)
|
2016-09-14 |
2025-01-28 |
特纳奥尼股份有限公司 |
Cd3结合抗体
|
|
WO2018058432A1
(zh)
*
|
2016-09-28 |
2018-04-05 |
李华顺 |
一种多基因重组嵌合抗原受体分子及其应用
|
|
WO2018068201A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
JP2020513248A
(ja)
|
2016-10-19 |
2020-05-14 |
フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． |
音響による親和性細胞抽出
|
|
CN106755108A
(zh)
*
|
2016-12-05 |
2017-05-31 |
刘晓明 |
一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
|
|
CN106755109A
(zh)
*
|
2016-12-05 |
2017-05-31 |
刘晓明 |
一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
|
|
CN106701827A
(zh)
*
|
2016-12-05 |
2017-05-24 |
刘晓明 |
表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
|
|
US10799536B2
(en)
|
2016-12-09 |
2020-10-13 |
Onk Therapeutics Limited |
Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
|
|
CN106822184A
(zh)
*
|
2016-12-15 |
2017-06-13 |
梁爱斌 |
多靶点联合的car‑t细胞制剂与制备方法
|
|
CN116284402A
(zh)
|
2016-12-21 |
2023-06-23 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
|
CN106749677B
(zh)
*
|
2017-01-04 |
2020-06-12 |
上海交通大学医学院附属瑞金医院 |
一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
|
|
EP3565841A1
(en)
|
2017-01-06 |
2019-11-13 |
Crescendo Biologics Limited |
Single domain antibodies to programmed cell death (pd-1)
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
WO2018151836A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
TW202515920A
(zh)
|
2017-04-11 |
2025-04-16 |
美商因荷布瑞克斯生物科學公司 |
具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
|
|
CN108728465A
(zh)
*
|
2017-04-14 |
2018-11-02 |
深圳新诺微环生物科技有限公司 |
一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
|
|
CN110741016A
(zh)
*
|
2017-04-26 |
2020-01-31 |
优瑞科生物技术公司 |
嵌合抗体/t-细胞受体构筑体及其用途
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200078404A1
(en)
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
JP7164598B2
(ja)
*
|
2017-05-17 |
2022-11-01 |
サンダー・バイオテック・インコーポレイテッド |
トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
CN107245500B
(zh)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
|
|
CN107299110B
(zh)
*
|
2017-05-27 |
2019-11-22 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
|
|
CN107337736B
(zh)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CA3065951A1
(en)
*
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
KR102742528B1
(ko)
*
|
2017-06-20 |
2024-12-16 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
WO2019000223A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2018291128B2
(en)
*
|
2017-06-30 |
2024-10-10 |
Teneobio, Inc. |
Anti-B-cell maturation antigen chimeric antigen receptors with human domains
|
|
GB201711068D0
(en)
|
2017-07-10 |
2017-08-23 |
Crescendo Biologics Ltd |
Therapeutic molecules binding PSMA
|
|
CN109232742B
(zh)
*
|
2017-07-11 |
2021-10-22 |
深圳市第二人民医院 |
一种嵌合抗原受体及其应用
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
US11976121B2
(en)
*
|
2017-07-20 |
2024-05-07 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
CD123-binding chimeric antigen receptors
|
|
WO2019014891A1
(zh)
*
|
2017-07-20 |
2019-01-24 |
深圳普瑞金生物药业有限公司 |
一种用于治疗肿瘤的egfr单域抗体cart及其应用
|
|
WO2019028051A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
|
WO2019046818A1
(en)
*
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
|
|
BR112020004846A2
(pt)
*
|
2017-09-13 |
2020-09-15 |
Teneobio, Inc. |
anticorpos de cadeia pesada que se ligam a ectoenzimas
|
|
JP7137619B2
(ja)
*
|
2017-09-29 |
2022-09-14 |
モガム・インスティテュート・フォー・バイオメディカル・リサーチ |
Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
PL3694529T3
(pl)
|
2017-10-13 |
2024-12-16 |
Harpoon Therapeutics, Inc. |
Trójswoiste białka i sposoby zastosowania
|
|
IL315737A
(en)
*
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019090003A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
KR20200080304A
(ko)
|
2017-11-13 |
2020-07-06 |
크레센도 바이오로직스 리미티드 |
Cd137에 결합하는 단일 도메인 항체
|
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
AU2018369883A1
(en)
*
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US10785574B2
(en)
|
2017-12-14 |
2020-09-22 |
Flodesign Sonics, Inc. |
Acoustic transducer driver and controller
|
|
US20190192678A1
(en)
*
|
2017-12-18 |
2019-06-27 |
Novather, Inc. |
System and method for the treatment of disease using a hyperspecific modified protein system
|
|
KR102752985B1
(ko)
|
2017-12-20 |
2025-01-10 |
포세이다 테라퓨틱스, 인크. |
Vcar 조성물 및 사용 방법
|
|
US20220218745A1
(en)
*
|
2017-12-22 |
2022-07-14 |
2Seventy Bio, Inc. |
Multivalent chimeric antigen receptor
|
|
CN109970860A
(zh)
*
|
2017-12-27 |
2019-07-05 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
CN109988242A
(zh)
*
|
2018-01-02 |
2019-07-09 |
武汉波睿达生物科技有限公司 |
联合嵌合抗原受体、表达载体、慢病毒及t细胞
|
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
CN108285486A
(zh)
*
|
2018-01-15 |
2018-07-17 |
浙江阿思科力生物科技有限公司 |
以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
|
CN108341881B
(zh)
*
|
2018-01-31 |
2020-08-18 |
深圳市默赛尔生物医学科技发展有限公司 |
带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN108314739B
(zh)
*
|
2018-02-05 |
2020-07-14 |
深圳市默赛尔生物医学科技发展有限公司 |
多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
|
|
CN110129369B
(zh)
*
|
2018-02-09 |
2023-10-13 |
上海交通大学医学院附属上海儿童医学中心 |
一种嵌合抗原受体基因工程载体、免疫细胞及其应用
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
GB201802573D0
(en)
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
CA3089230A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
CN108220247A
(zh)
*
|
2018-03-20 |
2018-06-29 |
杭州史迪姆生物科技有限公司 |
一种双car-t细胞及其制备方法和应用
|
|
AU2019249221A1
(en)
|
2018-04-06 |
2020-10-22 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
EP3549597A1
(en)
*
|
2018-04-06 |
2019-10-09 |
Heinrich-Heine-Universität Düsseldorf |
Synthetic signalling constructs and its use
|
|
EP3773632A4
(en)
*
|
2018-04-06 |
2022-05-18 |
The Regents of The University of California |
Methods of treating egfrviii expressing glioblastomas
|
|
KR20210006913A
(ko)
|
2018-04-11 |
2021-01-19 |
인히브릭스, 인크. |
제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
JOP20200292A1
(ar)
|
2018-05-16 |
2020-11-15 |
Stichting Vumc |
Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN110606893B
(zh)
*
|
2018-06-15 |
2022-11-15 |
北昊干细胞与再生医学研究院有限公司 |
一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
|
|
AU2019291627A1
(en)
*
|
2018-06-19 |
2020-10-08 |
Nanjing Legend Biotech Co., Ltd. |
Engineered cells and uses thereof
|
|
CN116769032A
(zh)
*
|
2018-07-20 |
2023-09-19 |
坦尼奥第二公司 |
与cd19结合的重链抗体
|
|
TW202035451A
(zh)
*
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
CA3109253A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
|
GB201813178D0
(en)
*
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
CN109134665B
(zh)
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
CN111542343B
(zh)
*
|
2018-08-24 |
2023-08-18 |
上海先博生物科技有限公司 |
抗bcma的单域抗体及其应用
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
WO2020047452A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CA3110750A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
|
CN109293781A
(zh)
*
|
2018-09-12 |
2019-02-01 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN109081870B
(zh)
*
|
2018-09-21 |
2021-12-03 |
成都阿帕克生物科技有限公司 |
一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
CN109265550B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Bcma抗体、嵌合抗原受体和药物
|
|
JP2022501067A
(ja)
*
|
2018-09-26 |
2022-01-06 |
上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. |
Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
CN109503716B
(zh)
*
|
2018-10-08 |
2021-04-27 |
浙江生研生物科技有限公司 |
一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
US20210388106A1
(en)
*
|
2018-10-26 |
2021-12-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
MA54079A
(fr)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
|
CN109504660B
(zh)
*
|
2018-11-02 |
2021-08-06 |
温州启星生物技术有限公司 |
一种第四代car-t细胞及其构建方法和应用
|
|
US12263190B2
(en)
|
2018-11-08 |
2025-04-01 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
CN109468283A
(zh)
*
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN110951689A
(zh)
*
|
2018-11-30 |
2020-04-03 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN113412117B
(zh)
*
|
2018-12-12 |
2025-03-04 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109485732B
(zh)
|
2018-12-20 |
2021-09-24 |
四川大学华西医院 |
基因工程修饰的双靶点嵌合抗原受体及其用途
|
|
CN109651511B
(zh)
*
|
2018-12-26 |
2020-06-09 |
广州百暨基因科技有限公司 |
一种靶向bcma的嵌合抗原受体及其应用
|
|
US20220144960A1
(en)
*
|
2018-12-26 |
2022-05-12 |
Nanjing Legend Biotech Co., Ltd. |
Cd30-binding moieties, chimeric antigen receptors, and uses thereof
|
|
CN109652379B
(zh)
*
|
2018-12-29 |
2022-08-16 |
博生吉医药科技(苏州)有限公司 |
Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
|
|
CN109485734B
(zh)
*
|
2018-12-30 |
2020-05-12 |
广州百暨基因科技有限公司 |
一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
EP3908613A4
(en)
*
|
2019-01-07 |
2022-10-19 |
Celluris Participações Ltda. |
BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
US12122843B2
(en)
|
2019-01-22 |
2024-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
CN113330038A
(zh)
*
|
2019-01-22 |
2021-08-31 |
亘喜生物科技（上海）有限公司 |
Cd20组合靶向的工程化免疫细胞
|
|
CA3128384A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
CN109734814A
(zh)
*
|
2019-02-12 |
2019-05-10 |
南京卡提医学科技有限公司 |
具有免疫受体的工程化t细胞治疗癌症的用途
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020191079A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
PH12021552123A1
(en)
|
2019-03-21 |
2022-08-22 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
MX2021012205A
(es)
|
2019-04-05 |
2022-02-21 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma.
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20230144237A1
(en)
*
|
2019-04-22 |
2023-05-11 |
Nanjing Legend Biotech Co., Ltd. |
Engineered cells and uses thereof
|
|
CN109942709B
(zh)
*
|
2019-04-22 |
2019-12-27 |
广州百暨基因科技有限公司 |
一种抗bcma的单域抗体及其应用
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
AU2020265679A1
(en)
|
2019-04-30 |
2021-12-23 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
EP3733707A1
(en)
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
US11560428B2
(en)
*
|
2019-05-04 |
2023-01-24 |
Inhibrx, Inc. |
CD33-binding polypeptides and uses thereof
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
WO2020247618A1
(en)
*
|
2019-06-04 |
2020-12-10 |
The General Hospital Corporation |
Antibodies and chimeric antigen receptors that target taci
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
MX2022000016A
(es)
*
|
2019-06-27 |
2022-02-24 |
Crispr Therapeutics Ag |
Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
CN110540997B
(zh)
*
|
2019-08-29 |
2024-02-13 |
浙江煦顼技术有限公司 |
靶向bcma嵌合抗原受体、核酸序列、载体及应用
|
|
JOP20220049A1
(ar)
*
|
2019-08-30 |
2023-01-30 |
Janssen Biotech Inc |
مشرعات وتركيبات car t خاصة بمركب نضج الخلايا البائية
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021043169A1
(zh)
*
|
2019-09-02 |
2021-03-11 |
成都盛世君联生物技术有限公司 |
特异性结合b细胞成熟抗原的抗体及其用途
|
|
WO2021054789A1
(ko)
*
|
2019-09-18 |
2021-03-25 |
주식회사 에스엘바이젠 |
신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
|
|
WO2021057866A1
(zh)
*
|
2019-09-26 |
2021-04-01 |
苏州克睿基因生物科技有限公司 |
一种单域抗体及包含抗体结构的嵌合抗原受体
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
EP4048292A4
(en)
*
|
2019-10-21 |
2024-06-19 |
Purdue Research Foundation |
Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
|
|
EP4031250A1
(en)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
BR112022008633A2
(pt)
|
2019-11-05 |
2022-07-19 |
Janssen Biotech Inc |
Terapia de células car-t direcionadas a bcma de mieloma múltiplo
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
US20230058044A1
(en)
*
|
2019-11-26 |
2023-02-23 |
Ramot At Tel-Aviv University Ltd. |
Chimeric antigen receptor to carbohydrate antigens
|
|
AU2020400801B2
(en)
*
|
2019-12-10 |
2024-11-14 |
Abl Bio, Inc. |
Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
|
|
US20230058669A1
(en)
*
|
2019-12-16 |
2023-02-23 |
Nanjing Legend Biotech Co., Ltd. |
Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
|
|
CN111171158B
(zh)
*
|
2020-01-17 |
2020-10-30 |
南京蓝盾生物科技有限公司 |
同时靶向bcma和cd38的嵌合抗原受体及其应用
|
|
CN111235113A
(zh)
*
|
2020-01-21 |
2020-06-05 |
南京北恒生物科技有限公司 |
包含嵌合抗原受体的免疫细胞及其用途
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
CN115397973A
(zh)
*
|
2020-01-30 |
2022-11-25 |
免疫生物公司 |
表达car的nk细胞消除bcma阳性恶性肿瘤
|
|
CN111196858B
(zh)
*
|
2020-02-05 |
2021-02-09 |
武汉科技大学 |
一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
|
|
US20240261329A1
(en)
*
|
2020-02-13 |
2024-08-08 |
Sichuan University |
Chimeric antigen receptor and use thereof
|
|
AU2021218441A1
(en)
*
|
2020-02-14 |
2022-09-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors with CD2 activation
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
IL296319A
(en)
*
|
2020-03-09 |
2022-11-01 |
Janssen Biotech Inc |
Compositions and methods for quantifying integration of recombinant vector nucleic acid
|
|
CN113402612A
(zh)
*
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
|
US20230165872A1
(en)
|
2020-04-28 |
2023-06-01 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
EP4186564A1
(en)
|
2020-04-29 |
2023-05-31 |
Teneoone, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
WO2021223705A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
CN111574629B
(zh)
*
|
2020-06-01 |
2021-07-20 |
宁夏医科大学 |
一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
|
|
CN111607565A
(zh)
*
|
2020-06-04 |
2020-09-01 |
河南大学 |
一种北平顶猴t细胞的体外扩增方法
|
|
JP2023530238A
(ja)
*
|
2020-06-08 |
2023-07-14 |
ヤンセン バイオテツク，インコーポレーテツド |
キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ
|
|
CA3181655A1
(en)
|
2020-06-08 |
2021-12-16 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
CA3171101A1
(en)
*
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
US20230242678A1
(en)
|
2020-06-26 |
2023-08-03 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
WO2022011531A1
(zh)
*
|
2020-07-14 |
2022-01-20 |
浙江道尔生物科技有限公司 |
一种抗cld18a2的单域抗体
|
|
WO2022012681A1
(en)
*
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric antigen receptors and uses thereof
|
|
JP2023546765A
(ja)
*
|
2020-07-16 |
2023-11-08 |
レジェンド バイオテック ユーエスエイ インコーポレイテッド |
Ｃｄ２０結合分子及びその使用
|
|
KR20230038706A
(ko)
*
|
2020-07-16 |
2023-03-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Cd19 결합 분자 및 이의 용도
|
|
AU2021307644A1
(en)
*
|
2020-07-16 |
2023-02-16 |
Legend Biotech Ireland Limited |
CD22 binding molecules and uses thereof
|
|
CN111848798B
(zh)
*
|
2020-07-27 |
2022-05-13 |
源道隆（苏州）医学科技有限公司 |
可结合bcma的纳米抗体及其应用
|
|
BR112023001452A2
(pt)
*
|
2020-07-29 |
2023-02-14 |
Nat Res Council Canada |
Anticorpos de domínio único anti-cd22 e construtos terapêuticos
|
|
CN111909271B
(zh)
*
|
2020-08-12 |
2021-03-23 |
深圳市茵冠生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及其应用
|
|
EP4196504A1
(en)
|
2020-08-13 |
2023-06-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
|
|
JP2023537958A
(ja)
|
2020-08-20 |
2023-09-06 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
|
|
KR20230045095A
(ko)
|
2020-08-20 |
2023-04-04 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
CN112062864A
(zh)
*
|
2020-09-18 |
2020-12-11 |
樊克兴 |
靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
|
|
CN112251412B
(zh)
*
|
2020-10-12 |
2023-03-28 |
汤朝阳 |
一种靶向bcma的嵌合抗原受体t细胞及其应用
|
|
CN111925451B
(zh)
*
|
2020-10-12 |
2021-01-29 |
佑仁细胞工程(浙江)有限公司 |
一种靶向bcma的嵌合抗原受体(car)及其应用
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CN112028996B
(zh)
*
|
2020-10-30 |
2021-01-22 |
南京北恒生物科技有限公司 |
靶向bcma的单域抗体及其用途
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022116086A1
(en)
*
|
2020-12-03 |
2022-06-09 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
EP4272002A1
(en)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
IL303610A
(en)
*
|
2020-12-17 |
2023-08-01 |
Parasol Biotech Ltd |
GUCY2C binding molecules and their uses
|
|
US12404315B2
(en)
|
2020-12-21 |
2025-09-02 |
Allogene Therapeutics, Inc. |
Protease-activating CD45-gate CAR
|
|
CN116390954A
(zh)
*
|
2020-12-29 |
2023-07-04 |
宁波茂行生物医药科技有限公司 |
靶向bcma的单域抗体
|
|
IL303473A
(en)
|
2020-12-31 |
2023-08-01 |
Sana Biotechnology Inc |
Methods and compositions for modulating car-t activity
|
|
CN113024671B
(zh)
*
|
2020-12-31 |
2022-05-24 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ８標的ウイルスベクターの使用方法
|
|
CN114149505B
(zh)
*
|
2021-01-12 |
2022-11-04 |
北京门罗生物科技有限公司 |
治疗b细胞相关疾病的免疫细胞、制备方法及其应用
|
|
CA3209218A1
(en)
*
|
2021-01-27 |
2022-08-04 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Bi-specific car t cells for b cell malignancies
|
|
CN112778427B
(zh)
*
|
2021-01-29 |
2022-03-15 |
武汉思安医疗技术有限公司 |
双特异性cs1-bcma car-t细胞及其应用
|
|
EP4284918A1
(en)
|
2021-01-29 |
2023-12-06 |
Allogene Therapeutics, Inc. |
Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
|
|
KR20230146032A
(ko)
|
2021-02-15 |
2023-10-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
|
|
WO2022183160A1
(en)
*
|
2021-02-25 |
2022-09-01 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Methods for treating cd83-expressing cancer
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
CN117924496A
(zh)
*
|
2021-03-22 |
2024-04-26 |
浙江纳米抗体技术中心有限公司 |
一种靶向bcma的纳米抗体及其应用
|
|
KR20230166090A
(ko)
*
|
2021-04-06 |
2023-12-06 |
테네오바이오, 인코포레이티드 |
항-cd19 항체 및 car-t 구조체
|
|
WO2022221844A2
(en)
*
|
2021-04-13 |
2022-10-20 |
WUGEN, Inc. |
Improved chimeric antigen receptors and uses thereof
|
|
EP4324853A4
(en)
|
2021-04-15 |
2025-07-16 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
MULTI-SPECIFIC ANTIBODY TARGETING BCMA
|
|
CN117529333A
(zh)
|
2021-04-16 |
2024-02-06 |
细胞基因公司 |
对先前进行过干细胞移植的患者的t细胞疗法
|
|
CR20230525A
(es)
*
|
2021-04-16 |
2024-02-19 |
Teneobio Inc |
Anticuerpos anti-cd20 y estructuras car-t
|
|
JP2024514163A
(ja)
|
2021-04-16 |
2024-03-28 |
セルジーン コーポレーション |
Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022228579A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antigen receptors targeting gpc3 and methods of use thereof
|
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
CA3217687A1
(en)
|
2021-05-11 |
2022-11-17 |
Muhammad S. AKRAM |
Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy
|
|
AU2022277931A1
(en)
|
2021-05-19 |
2023-11-30 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
JP2024519869A
(ja)
*
|
2021-05-19 |
2024-05-21 |
セレディット エルエルシー |
二重特異性キメラ抗原受容体、及びそれを発現する遺伝子操作された免疫細胞
|
|
CA3216346A1
(en)
|
2021-05-27 |
2022-12-01 |
Edward Rebar |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
WO2022261017A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
CA3225283A1
(en)
|
2021-07-14 |
2023-01-19 |
Sonja SCHREPFER |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
CN113651893B
(zh)
*
|
2021-08-12 |
2023-08-01 |
上海生物制品研究所有限责任公司 |
联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
|
|
CA3228773A1
(en)
*
|
2021-08-12 |
2023-02-16 |
Gaurav KHARYA |
Chimeric antigen receptors (car) for b cell malignancies
|
|
TW202323521A
(zh)
|
2021-08-20 |
2023-06-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
US11359012B1
(en)
|
2021-08-27 |
2022-06-14 |
Nanjing Kaedi Biotherapeutics Ltd. |
Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof
|
|
US11970548B2
(en)
|
2021-08-27 |
2024-04-30 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nanobody target GCC and uses in chimeric antigen receptor cell therapy
|
|
CN117586404A
(zh)
*
|
2021-09-24 |
2024-02-23 |
四川大学 |
可特异性靶向人EpCAM抗原的纳米抗体及应用
|
|
WO2023056313A1
(en)
*
|
2021-09-29 |
2023-04-06 |
Modex Therapeutics |
Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
|
|
US20250000976A1
(en)
*
|
2021-10-07 |
2025-01-02 |
National Research Council Of Canada |
Anti-bcma single domain antibodies and therapeutic constructs
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
US20240417446A1
(en)
|
2021-10-26 |
2024-12-19 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
CN114015674B
(zh)
|
2021-11-02 |
2024-08-30 |
辉大(上海)生物科技有限公司 |
一种CRISPR-Cas12i系统
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
EP4426435A1
(en)
|
2021-11-03 |
2024-09-11 |
Janssen Biotech, Inc. |
Corticosteriod reduction in treatment with anti-cd38 antibodies
|
|
WO2023077343A1
(en)
|
2021-11-04 |
2023-05-11 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
CA3237341A1
(en)
|
2021-11-04 |
2023-05-11 |
Nanjing Legend Biotech Co., Ltd. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
JP2024540360A
(ja)
|
2021-11-09 |
2024-10-31 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
グリピカン－３（ＧＰＣ３）を標的にするＩｇＧ４ヒンジ含有キメラ抗原受容体およびその使用
|
|
CN115466331B
(zh)
*
|
2021-11-18 |
2023-05-30 |
合源生物科技(天津)有限公司 |
靶向bcma的嵌合抗原受体及其应用
|
|
WO2023104100A1
(zh)
*
|
2021-12-07 |
2023-06-15 |
信达细胞制药(苏州)有限公司 |
结合bcma的抗体及其用途
|
|
CN114195898B
(zh)
*
|
2021-12-13 |
2022-10-28 |
南京凯地医疗技术有限公司 |
人源化抗cd33的单域抗体及其构建体制备方法和应用
|
|
WO2023109257A1
(zh)
*
|
2021-12-16 |
2023-06-22 |
浙江瑞加美生物科技有限公司 |
人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
|
|
US20240408192A1
(en)
|
2021-12-17 |
2024-12-12 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
MX2024007528A
(es)
|
2021-12-23 |
2024-08-30 |
Sana Biotechnology Inc |
Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
|
|
JP2025508298A
(ja)
*
|
2021-12-29 |
2025-03-26 |
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー |
シングルドメイン高親和性抗体及びその使用方法
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250144214A1
(en)
|
2022-02-15 |
2025-05-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
|
|
IL315000A
(en)
|
2022-02-17 |
2024-10-01 |
Sana Biotechnology Inc |
Engineered cd47 proteins and uses thereof
|
|
CA3252674A1
(en)
|
2022-02-28 |
2023-08-31 |
Nanjing Legend Biotech Co., Ltd. |
BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
AU2023248532A1
(en)
|
2022-04-08 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Multipartite receptor and signaling complexes
|
|
CN114685664B
(zh)
*
|
2022-04-12 |
2023-10-20 |
内蒙古农业大学 |
抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
CN119212724A
(zh)
*
|
2022-05-09 |
2024-12-27 |
上海先博生物科技有限公司 |
工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4522183A2
(en)
|
2022-05-11 |
2025-03-19 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
US20250319129A1
(en)
*
|
2022-05-27 |
2025-10-16 |
Suzhou Immunofoco Biotechnology Co., Ltd |
Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
|
|
EP4536710A1
(en)
*
|
2022-06-13 |
2025-04-16 |
The Regents of the University of California |
Humanized antibodies to human integrin avb8
|
|
US12297285B2
(en)
*
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
CN114805582B
(zh)
*
|
2022-06-29 |
2022-10-04 |
上海恒润达生生物科技股份有限公司 |
抗Trop2纳米抗体及其用途
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024026455A2
(en)
*
|
2022-07-29 |
2024-02-01 |
Shoreline Biosciences, Inc. |
Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
|
|
WO2024026445A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
WO2024041650A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
CN116023495B
(zh)
*
|
2022-09-05 |
2023-10-03 |
上海百英生物科技股份有限公司 |
一种抗cd40纳米抗体及其制备方法与应用
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
CN115925947B
(zh)
*
|
2022-09-27 |
2023-08-22 |
上海百英生物科技股份有限公司 |
一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
CN117384299B
(zh)
*
|
2022-11-01 |
2024-04-30 |
邦恩泰(山东)生物医药科技集团股份有限公司 |
靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
IL320528A
(en)
*
|
2022-11-02 |
2025-06-01 |
Legend Biotech Usa Inc |
Bcma-targeted car-t cell therapy of multiple myeloma
|
|
WO2024097979A1
(en)
*
|
2022-11-04 |
2024-05-10 |
Dana-Farber Cancer Institute, Inc. |
Bcma vh-only cars
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
CN117069844B
(zh)
*
|
2022-12-06 |
2024-02-09 |
成都赛恩吉诺生物科技有限公司 |
包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
|
|
EP4630446A1
(en)
|
2022-12-06 |
2025-10-15 |
Dynamic Cell Therapies, Inc. |
Engineered switches for immune cell activity and methods of use thereof
|
|
EP4630043A1
(en)
|
2022-12-06 |
2025-10-15 |
Dynamic Cell Therapies, Inc. |
Immune-activating complexes
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
KR20250121074A
(ko)
|
2022-12-09 |
2025-08-11 |
주노 쎄러퓨티크스 인코퍼레이티드 |
홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
|
|
KR20240094169A
(ko)
*
|
2022-12-13 |
2024-06-25 |
진셀비티 주식회사 |
B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
|
|
CN115947853B
(zh)
*
|
2022-12-26 |
2024-06-28 |
河北森朗生物科技有限公司 |
靶向bcma的纳米抗体、嵌合抗原受体及其应用
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
CN116199781B
(zh)
*
|
2023-02-22 |
2025-07-18 |
成都优赛诺生物科技有限公司 |
一种靶向cd22的单域抗体、嵌合抗原受体及其应用
|
|
WO2024175657A1
(en)
|
2023-02-22 |
2024-08-29 |
Astrazeneca Ab |
Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
|
|
WO2024206209A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
|
|
CN120641113A
(zh)
|
2023-03-31 |
2025-09-12 |
西比曼生物科技集团 |
靶向cd20和bcma的双特异性嵌合抗原受体
|
|
CN116640229B
(zh)
*
|
2023-04-10 |
2024-01-30 |
中国人民解放军总医院第五医学中心 |
一种低pH靶向性CAR-T细胞的构建及应用
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
CA3205511A1
(en)
*
|
2023-04-19 |
2025-03-17 |
Janssen Biotech, Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
CN119486745A
(zh)
*
|
2023-05-24 |
2025-02-18 |
茂行制药(苏州)有限公司 |
用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
CN116655805B
(zh)
*
|
2023-05-31 |
2024-03-08 |
四川大学华西医院 |
一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
CN116789859B
(zh)
*
|
2023-06-29 |
2024-02-23 |
徐州医科大学 |
一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
|
|
CN116949099B
(zh)
*
|
2023-07-12 |
2024-04-02 |
山东大学第二医院 |
一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
GR1010884B
(el)
*
|
2023-08-30 |
2025-02-19 |
Janssen Biotech, Inc., |
Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
CN117024594B
(zh)
*
|
2023-09-21 |
2025-02-28 |
武汉波睿达生物科技有限公司 |
一种抗cd20的纳米抗体及其应用
|
|
WO2025067472A1
(en)
*
|
2023-09-27 |
2025-04-03 |
Nanjing Legend Biotech Co., Ltd. |
Methods of culturing gamma delta t cells
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
TW202530413A
(zh)
|
2023-10-05 |
2025-08-01 |
美商健生生物科技公司 |
用於生產ｃａｒ－ｔ細胞藥品之慢病毒製造的改良方法
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025096560A1
(en)
|
2023-10-30 |
2025-05-08 |
Allogene Therapeutics, Inc. |
Engineered cells
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US20250144234A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics Inc. |
RNA for In vivo Transfection with Increased Expression
|
|
GB202317065D0
(en)
|
2023-11-07 |
2023-12-20 |
Coding Bio Ltd |
BCMA binding molecules
|
|
WO2025098446A1
(zh)
*
|
2023-11-07 |
2025-05-15 |
赛斯尔擎生物技术（上海）有限公司 |
抗bcma单域抗体及其应用
|
|
CN120025440A
(zh)
*
|
2023-11-21 |
2025-05-23 |
南京融捷康生物科技有限公司 |
一种抗Nkp46的单域抗体及其用途
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025130984A1
(en)
*
|
2023-12-20 |
2025-06-26 |
Overland Therapeutics (Us) Inc. |
Single domain antibodies for bcma
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
KR102869233B1
(ko)
*
|
2024-01-24 |
2025-10-15 |
주식회사 박셀바이오 |
Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250269024A1
(en)
|
2024-02-05 |
2025-08-28 |
Legend Biotech Usa Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
CN117866904B
(zh)
*
|
2024-03-12 |
2024-06-07 |
北京贝来药业有限公司 |
基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
|
|
US20250339527A1
(en)
|
2024-03-12 |
2025-11-06 |
Legend Biotech Usa Inc. |
Bcma-targeted car-t cell therapy for multiple myeloma
|
|
CN117866903B
(zh)
*
|
2024-03-12 |
2024-06-04 |
北京贝来药业有限公司 |
单域抗体修饰的干细胞及其在疾病治疗中用途
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025221781A2
(en)
|
2024-04-15 |
2025-10-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
|
|
WO2025231372A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025232812A1
(en)
*
|
2024-05-08 |
2025-11-13 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Biomolecule conjugated lipid nanoparticles
|
|
WO2025235598A1
(en)
|
2024-05-09 |
2025-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
|
|
WO2025240496A1
(en)
|
2024-05-14 |
2025-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
|
|
WO2025255266A1
(en)
|
2024-06-05 |
2025-12-11 |
Dynamic Cell Therapies, Inc. |
Engineered polypeptides for immune cell activation
|
|
CN120173114B
(zh)
*
|
2025-03-24 |
2025-09-26 |
广州泽朗生物医药科技有限公司 |
Cart细胞及其在制备抗癌症药物中的应用
|